EA201990171A1 - Биспецифичное антитело против egfr и против cd3 и его применения - Google Patents

Биспецифичное антитело против egfr и против cd3 и его применения

Info

Publication number
EA201990171A1
EA201990171A1 EA201990171A EA201990171A EA201990171A1 EA 201990171 A1 EA201990171 A1 EA 201990171A1 EA 201990171 A EA201990171 A EA 201990171A EA 201990171 A EA201990171 A EA 201990171A EA 201990171 A1 EA201990171 A1 EA 201990171A1
Authority
EA
Eurasian Patent Office
Prior art keywords
egfr
antibody
bispecific
bispecific antibody
application
Prior art date
Application number
EA201990171A
Other languages
English (en)
Inventor
И Бай
Вэнь Чзан
Мэн СЮЙ
Шуан Пэй
Яньлу Цзань
Шэнмэй Вэнь
Original Assignee
Бейдзин Дунфан Байотек Ко. Лтд.
Бейдзин Цзинитайсян Текноложи Дивелопмент Ко. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бейдзин Дунфан Байотек Ко. Лтд., Бейдзин Цзинитайсян Текноложи Дивелопмент Ко. Лтд. filed Critical Бейдзин Дунфан Байотек Ко. Лтд.
Publication of EA201990171A1 publication Critical patent/EA201990171A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Предложено биспецифичное антитело против рецептора эпидермального фактора роста (EGFR) и против кластера дифференциации (CD3) и его применение. Данное биспецифичное антитело может специфично связываться с антигеном - рецептором эпидермального фактора роста (EGFR) - на поверхности опухолевой клетки и с антигеном - молекулой CD3 - на поверхности иммунной клетки. Одноцепочечное антитело (ScFv) антитела против CD3 расположено на С-конце константной области антитела против EGFR. Кроме того, предложен способ получения биспецифичного антитела и клинические применения данного биспецифичного антитела. Биспецифичное антитело имеет высокую аффинность и используется для лечения опухолевых заболеваний, вызванных высокой экспрессией или ненормальной экспрессией EGFR, и других заболеваний, вызванных другой сверхэкспрессией EGFR.
EA201990171A 2016-10-11 2017-09-28 Биспецифичное антитело против egfr и против cd3 и его применения EA201990171A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610886938.7A CN106632681B (zh) 2016-10-11 2016-10-11 抗egfr和抗cd3双特异抗体及其应用
PCT/CN2017/103896 WO2018068652A1 (zh) 2016-10-11 2017-09-28 抗egfr和抗cd3双特异抗体及其应用

Publications (1)

Publication Number Publication Date
EA201990171A1 true EA201990171A1 (ru) 2019-07-31

Family

ID=58855294

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990171A EA201990171A1 (ru) 2016-10-11 2017-09-28 Биспецифичное антитело против egfr и против cd3 и его применения

Country Status (9)

Country Link
US (1) US11396547B2 (ru)
EP (1) EP3527590A4 (ru)
JP (1) JP6821006B2 (ru)
KR (1) KR102179674B1 (ru)
CN (1) CN106632681B (ru)
AU (1) AU2017343414B2 (ru)
CA (1) CA3032560C (ru)
EA (1) EA201990171A1 (ru)
WO (1) WO2018068652A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106632681B (zh) 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
CN107880131A (zh) * 2017-08-14 2018-04-06 四川大学 一种抗IL‑13Rα2和CD3双特异抗体及其应用
PE20212205A1 (es) 2017-09-08 2021-11-18 Maverick Therapeutics Inc Proteinas de union condicionalmente activadas restringidas
CN111315773A (zh) * 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
KR20200143436A (ko) * 2018-04-13 2020-12-23 아피메트 게엠베하 Nk 세포 결합 항체 융합 구조체
CN110872356B (zh) * 2018-09-03 2023-06-13 广西慧宝源健康产业有限公司 双特异性抗体及其使用方法
CN112955471B (zh) * 2018-12-07 2022-11-22 江苏恒瑞医药股份有限公司 Cd3抗体及其药物用途
CN109776683B (zh) * 2019-03-19 2020-04-07 益科思特(北京)医药科技发展有限公司 一种双特异性抗体及其制备方法与应用
US11912767B2 (en) * 2019-03-22 2024-02-27 Regeneron Pharmaceuticals, Inc. EGFR × CD28 multispecific antibodies
CN110172100B (zh) * 2019-05-06 2021-03-19 北京智仁美博生物科技有限公司 抗人cd3e抗体及其用途
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US20230312729A1 (en) * 2019-06-26 2023-10-05 Amunix Pharmaceuticals, Inc. Egfr antigen binding fragments and compositions comprising same
CN110698563A (zh) * 2019-09-17 2020-01-17 深圳容金科技有限公司 多价抗体及其制备方法
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
WO2023183766A1 (en) * 2022-03-20 2023-09-28 Abcellera Biologics Inc. Anti-cd3 antibodies and t-cell engagers and methods of use
WO2023198042A1 (zh) * 2022-04-11 2023-10-19 江苏恒瑞医药股份有限公司 特异性结合egfr和cd28的抗原结合分子及其医药用途
CN114621351B (zh) * 2022-04-27 2023-01-03 华羊生物技术股份有限公司 多特异性抗体及其治疗癌症的用途
CN115029318B (zh) * 2022-05-12 2022-12-20 成都赋智健康科技有限公司 携带多特异性抗体基因的间充质干细胞及其制药用途
WO2024067222A1 (en) * 2022-09-30 2024-04-04 Nona Biosciences (Suzhou) Co., Ltd. Cd3-targeting antibody and use thereof
CN116239700A (zh) * 2022-12-20 2023-06-09 浙江大学 一种肿瘤双靶向的三特异性t细胞衔接器及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
NZ543202A (en) * 2003-05-31 2008-04-30 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for epcam
JP5026072B2 (ja) * 2003-07-01 2012-09-12 イミューノメディクス、インコーポレイテッド 二重特異性抗体の多価キャリヤー
CN1326881C (zh) * 2003-09-29 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 一种三价双特异性抗体，其制备方法及用途
JP2012034668A (ja) * 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
JP6441079B2 (ja) 2011-12-19 2018-12-19 シンイミューン ゲーエムベーハー 二重特異性抗体分子
JP5970197B2 (ja) 2012-02-08 2016-08-17 メルクパフォーマンスマテリアルズマニュファクチャリング合同会社 無機ポリシラザン樹脂
WO2014165818A2 (en) * 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
HRP20220553T1 (hr) 2013-07-25 2022-06-10 Cytomx Therapeutics Inc. Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
CN104341504B (zh) * 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
PE20160724A1 (es) * 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t
JPWO2015146437A1 (ja) * 2014-03-25 2017-04-13 国立大学法人東北大学 高機能性ＩｇＧ２型二重特異性抗体
US20170274072A1 (en) * 2014-03-26 2017-09-28 Tohoku University Bispecific antibody targeting human epidermal growth factor receptor
US9611325B2 (en) * 2014-07-21 2017-04-04 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody HER2xCD3
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
CN113150165A (zh) * 2014-12-22 2021-07-23 西雅图免疫公司 双特异性四价抗体及其制造和使用方法
EP3245227A4 (en) * 2015-01-14 2018-07-25 Compass Therapeutics LLC Multispecific immunomodulatory antigen-binding constructs
CN104774268B (zh) * 2015-01-21 2018-09-28 武汉友芝友生物制药有限公司 一种双特异性抗体egfr×cd3的构建及应用
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用

Also Published As

Publication number Publication date
CA3032560C (en) 2021-12-28
KR20190025004A (ko) 2019-03-08
CN106632681B (zh) 2017-11-14
CA3032560A1 (en) 2018-04-19
WO2018068652A1 (zh) 2018-04-19
AU2017343414A1 (en) 2019-02-28
JP2019526246A (ja) 2019-09-19
US20210277127A1 (en) 2021-09-09
JP6821006B2 (ja) 2021-01-27
US11396547B2 (en) 2022-07-26
CN106632681A (zh) 2017-05-10
KR102179674B1 (ko) 2020-11-18
EP3527590A4 (en) 2020-05-27
AU2017343414B2 (en) 2020-03-26
EP3527590A1 (en) 2019-08-21

Similar Documents

Publication Publication Date Title
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
PH12019502640A1 (en) Antibodies specific for flt3 and their uses
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EA201890028A1 (ru) Антитело, связывающее cd3 человека
PH12019500655A1 (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
AR111418A1 (es) Dominios de unión a antígeno humanizados y métodos de uso
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
NZ750221A (en) Anti-pd-1 antibodies, method for producing same and method for using same
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
NZ594682A (en) Fully human antibodies specific to cadm1
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
SG10201801219VA (en) Anti-HER2 Antibodies
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
EA202091569A1 (ru) Моноклональные антитела и способы их применения
ZA202008095B (en) Humanized antibodies against psma
PH12020551187A1 (en) Bispecific antigen-binding molecules and methods of use
MX2013011414A (es) Novedoso anticuerpo anti-receptor de il-23 humano.
WO2018231339A3 (en) TYROSINE PHOSPHORYLATED ANTI-PD-1 ANTIBODIES AND USES THEREOF
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.